BCR and chronic myelogenous leukemia, BCR-ABL1 positive: One example is Gleevec, a selective inhibitor of the BCR-ABL tyrosine kinase, the pathogenic fusion transcript in chronic myeloid leukemia (CML) (Hernández-Boluda and Cervantes 2002).